The Potential Role of Genomic Signature in Stage II Relapsed Colorectal Cancer (CRC) Patients: A Mono-Institutional Study

PURPOSE: The absolute benefit of adjuvant chemotherapy in stage II CRC is only 3–4%. The identification of biomarkers through molecular profiling could identify patients who will more benefit from adjuvant chemotherapy. PATIENTS AND METHODS: This retrospective analysis examined tissue blocks from 17...

Descripción completa

Detalles Bibliográficos
Autores principales: Roberto, Michela, Arrivi, Giulia, Pilozzi, Emanuela, Montori, Andrea, Balducci, Genoveffa, Mercantini, Paolo, Laghi, Andrea, Ierinò, Debora, Panebianco, Martina, Marinelli, Daniele, Tomao, Silverio, Marchetti, Paolo, Mazzuca, Federica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000544/
https://www.ncbi.nlm.nih.gov/pubmed/35418781
http://dx.doi.org/10.2147/CMAR.S342612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000544/
https://www.ncbi.nlm.nih.gov/pubmed/35418781
http://dx.doi.org/10.2147/CMAR.S342612

Ejemplares similares